Tirzepatide enhances glucose-dependent insulin secretion, reduces glucagon levels, delays gastric emptying, and improves insulin sensitivity, making it a promising therapeutic option for managing both hyperglycemia and obesity in patients with type 2 diabetes. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.